Otonomy, Inc.
(NASDAQ : OTIC)

( )
OTIC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.10%159.870.0%$1295.48m
AMGNAmgen, Inc. 2.21%255.131.3%$694.68m
SNSSSunesis Pharmaceuticals, Inc. 1.90%8.030.7%$561.33m
NVAXNovavax, Inc. 0.37%202.0980.0%$556.50m
ILMNIllumina, Inc. 0.98%401.963.5%$517.94m
GILDGilead Sciences, Inc. 0.72%65.771.0%$463.29m
REGNRegeneron Pharmaceuticals, Inc. 2.80%494.642.7%$449.68m
VRTXVertex Pharmaceuticals, Inc. 1.83%221.101.9%$383.88m
ALXNAlexion Pharmaceuticals, Inc. 1.45%157.542.0%$298.86m
BNTXBioNTech SE 6.12%140.720.0%$266.37m
BIIBBiogen, Inc. 1.75%270.441.7%$264.45m
EXASEXACT Sciences Corp. 2.66%130.5218.4%$192.20m
NBIXNeurocrine Biosciences, Inc. -0.05%95.004.9%$177.73m
CRSPCRISPR Therapeutics AG 0.60%123.850.6%$174.50m
SGENSeagen Inc. 3.77%149.645.8%$153.69m

Company Profile

Otonomy, Inc. operates as a biopharmaceutical company. It engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.